Aug. 10, 2020 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology
leader providing innovative cancer detection and therapy solutions, today
announced that Michael Klein, Chairman and Chief Executive Officer, will
present a corporate overview at the Guggenheim MedTech Disruptors Summit,
taking place virtually on August 10-11, 2020.
in Nashua, NH, iCAD is a global medical technology leader providing innovative
cancer detection and therapy solutions.
is a high-performing workflow solution for 2D and 3D mammography, or digital
breast tomosynthesis (DBT), featuring the latest in deep-learning artificial
intelligence. In 2018, ProFound AI for Digital Breast Tomosynthesis (DBT)
became the first artificial intelligence (AI) software for DBT to be
FDA-cleared; it was also CE marked and Health Canada licensed that same year.
It offers clinically proven time-savings benefits to radiologists, including a
reduction of reading time by 52.7 percent, thereby halving the amount of time
it takes radiologists to read 3D mammography datasets. Additionally, ProFound
AI for DBT improved radiologist sensitivity by 8 percent and reduced
unnecessary patient recall rates by 7.2 percent.i
System is FDA-cleared, CE marked and licensed in a growing number of countries
for the treatment of cancer anywhere in the body. It uses a proprietary
miniaturized x-ray source to deliver a precise, concentrated dose of radiation
directly to the tumor site, while minimizing risk of damage to healthy tissue
in nearby areas of the body.
Jessica Burns, iCAD
i Conant, E. et al. (2019). Improving Accuracy and Efficiency with
Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis.
Radiology: Artificial Intelligence. 1 (4). Accessed via https://pubs.rsna.org/doi/10.1148/ryai.2019180096